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echocardiographic signs of pulmonary hypertension at 
the initial presentation [6]. Interestingly, the development 
of CTEPH is not associated with common risk factors for 
venous thromboembolism, such as factor V Leiden, factor 
II mutation, deficiency of antithrombin, protein C and pro-
tein S or a prothrombin G20210A gene mutation [7]. The 
prevalence of these factors is low in CTEPH and some of 
them seem to occur with similar frequency among patients 
with CTEPH and the general population. There are two 
exceptions. The presence of antiphospholipid antibodies 
and Lupus anticoagulant is found in 10–20 % of the CTEPH 
patients and antiphospholipid antibodies predispose to acute 
venous thromboembolism and in some cases even recurrent 
pulmonary embolism [6,8−10].The study of D’Armini et 
al. compared 28 patients with high levels of antiphospho-
lipid antibodies with 156 patients with low level or absence 
of antiphospholipid antibodies who all underwent pulmo-
nary endarterectomy. There was no difference between the 
two groups after surgery in terms of mortality and major 
complications. However, the patients with high levels of 
antiphospholipid antibodies had significantly more transient 
neurological complications postoperatively [11].
Several studies demonstrated increased levels of FVIII in 
CTEPH patients [12−14]. One study investigated the effect 
of pulmonary endarterectomy on FVIII levels, and found 
no change after surgery. Interestingly, the level of FVIII 
decreases after medical treatment of pulmonary arterial 
hypertension (PAH) [15]. However, the exact mechanism of 
how these factors contribute to CTEPH remains unknown. 
To our knowledge, there are no studies comparing methy-
lenetetrahydrofolate reductase (MTHFR) C677T poly-
morphism between CTEPH patients and healthy controls. 
Furthermore, MTHFR polymorphism is not associated with 
PAH [16].
We would like to thank Dr. Correale et al. for their inter-
est and valuable comments on our review regarding the 
diagnostic approach to chronic thromboembolic pulmonary 
hypertension (CTEPH) and the available surgical and medi-
cal therapeutic options [1]. They ask for further comments 
on congenital abnormalities causing hypercoagulability in 
these patients.
The prevalence of CTEPH after acute pulmonary embo-
lism is estimated at 0.1–4.0 % after 2 years [2−5]. It is still 
not known why some patients develop CTEPH after acute 
pulmonary embolism and others do not. The risk of devel-
oping CTEPH is increased in patients who have recurrent 
venous thromboembolism, large perfusion defects and 
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Routine screening for thrombophilia seems only reason-
able when it has an impact on the prognosis, treatment or 
outcome of CTEPH. We must keep in mind that all patients 
receive life-long anticoagulant treatment. In the literature, 
only high levels of antiphospholipid antibodies were dem-
onstrated to influence postoperative outcome after pulmo-
nary endarterectomy. Therefore, according to the guideline, 
we think that screening for the antiphospholipid syndrome 
is reasonable [17].
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